|
US10022352B2
(en)
|
2006-04-07 |
2018-07-17 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-binding cassette transporters
|
|
USRE50453E1
(en)
|
2006-04-07 |
2025-06-10 |
Vertex Pharmaceuticals Incorporated |
Indole derivatives as CFTR modulators
|
|
US7645789B2
(en)
|
2006-04-07 |
2010-01-12 |
Vertex Pharmaceuticals Incorporated |
Indole derivatives as CFTR modulators
|
|
PT2674428T
(pt)
|
2006-04-07 |
2016-07-14 |
Vertex Pharma |
Modeladores de transportadores de cassetes de ligação de atp
|
|
US8217177B2
(en)
*
|
2006-07-14 |
2012-07-10 |
Amgen Inc. |
Fused heterocyclic derivatives and methods of use
|
|
US8198448B2
(en)
|
2006-07-14 |
2012-06-12 |
Amgen Inc. |
Fused heterocyclic derivatives and methods of use
|
|
PE20121506A1
(es)
|
2006-07-14 |
2012-11-26 |
Amgen Inc |
Compuestos triazolopiridinas como inhibidores de c-met
|
|
JP2010500365A
(ja)
|
2006-08-07 |
2010-01-07 |
インサイト・コーポレイション |
キナーゼ阻害剤としてのトリアゾロトリアジン
|
|
US8563573B2
(en)
|
2007-11-02 |
2013-10-22 |
Vertex Pharmaceuticals Incorporated |
Azaindole derivatives as CFTR modulators
|
|
BRPI0719333A2
(pt)
|
2006-11-22 |
2014-02-04 |
Incyte Corp |
Midazotriazinas e imidazopirimidinas como inbidores de cinase
|
|
WO2009106577A1
(en)
|
2008-02-28 |
2009-09-03 |
Novartis Ag |
Imidazo [1,2-b] pyridazine derivatives for the treatment of c-met tyrosine kinase mediated disease
|
|
BRPI0912882A2
(pt)
|
2008-05-21 |
2017-05-16 |
Incyte Corp |
sais de 2-flúor-n-metil-4-[7-(quinolin-6-il-metil)-imidazo[1,2-b][1,2,4]triazin-2-il]benzamida e processos relacionados à preparação dos mesmos
|
|
DE102008028905A1
(de)
|
2008-06-18 |
2009-12-24 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
|
|
DE102008037790A1
(de)
|
2008-08-14 |
2010-02-18 |
Merck Patent Gmbh |
Bicyclische Triazolderivate
|
|
DE102008038221A1
(de)
|
2008-08-18 |
2010-02-25 |
Merck Patent Gmbh |
7-Azaindolderivate
|
|
DE102008038222A1
(de)
|
2008-08-18 |
2010-02-25 |
Merck Patent Gmbh |
Indazol-5-carbonsäurehydrazid-derivate
|
|
DE102008038220A1
(de)
|
2008-08-18 |
2010-02-25 |
Merck Patent Gmbh |
Oxadiazolderivate
|
|
US8592448B2
(en)
|
2008-11-20 |
2013-11-26 |
OSI Pharmaceuticals, LLC |
Substituted pyrrolo[2,3-b]-pyridines and -pyrazines
|
|
WO2010068292A1
(en)
|
2008-12-12 |
2010-06-17 |
Ariad Pharmaceuticals, Inc. |
Azaindole derivatives as kinase inhibitors
|
|
DE102008063667A1
(de)
|
2008-12-18 |
2010-07-01 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-°[1,2,4]triazolo[4,3-b]pyrimidin-derivate
|
|
DE102008062825A1
(de)
|
2008-12-23 |
2010-06-24 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo [4,3-b]pyridazin-derivate
|
|
KR20110113755A
(ko)
*
|
2009-02-10 |
2011-10-18 |
아스트라제네카 아베 |
트리아졸로 〔4,3-b〕 피리다진 유도체 및 전립샘암에 대한 이의 용도
|
|
JP2012519731A
(ja)
*
|
2009-03-09 |
2012-08-30 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
ニコチン受容体およびgabaa受容体のアロステリックモジュレーターとしての置換複素環およびそれらの使用
|
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
|
EA201200260A1
(ru)
|
2009-08-12 |
2012-09-28 |
Новартис Аг |
Гетероциклические гидразоны и их применение для лечения рака и воспаления
|
|
IN2012DN01453A
(OSRAM)
|
2009-08-20 |
2015-06-05 |
Novartis Ag |
|
|
PL2719699T3
(pl)
*
|
2009-12-31 |
2016-01-29 |
Hutchison Medipharma Ltd |
Pewne triazolopirazyny, ich kompozycje i sposoby ich stosowania
|
|
MX2012008898A
(es)
|
2010-02-03 |
2012-11-06 |
Incyte Corp |
Imidazo - [1, 2 - b] [1, 2, 4] triazinas como inhibidores de c - met.
|
|
US8802868B2
(en)
|
2010-03-25 |
2014-08-12 |
Vertex Pharmaceuticals Incorporated |
Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
|
|
CA2797118C
(en)
*
|
2010-04-22 |
2021-03-30 |
Vertex Pharmaceuticals Incorporated |
Process of producing cycloalkylcarboxamido-indole compounds
|
|
JP2013526570A
(ja)
|
2010-05-14 |
2013-06-24 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
縮合二環式キナーゼ阻害剤
|
|
AR081039A1
(es)
|
2010-05-14 |
2012-05-30 |
Osi Pharmaceuticals Llc |
Inhibidores biciclicos fusionados de quinasa
|
|
EP2571878B1
(en)
|
2010-05-17 |
2018-10-17 |
Incozen Therapeutics Pvt. Ltd. |
Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b]pyridine compounds as modulators of protein kinases
|
|
US10414760B2
(en)
|
2016-11-29 |
2019-09-17 |
Angion Biomedica Corp. |
Cytochrome P450 inhibitors and uses thereof
|
|
AU2011261586B2
(en)
*
|
2010-06-01 |
2015-08-27 |
Angion Biomedica Corp. |
Cytochrome P450 inhibitors and uses thereof
|
|
AR085183A1
(es)
|
2010-07-30 |
2013-09-18 |
Lilly Co Eli |
Compuesto 6-(1-metil-1h-pirazol-4-il)-3-(2-metil-2h-indazol-5-iltio)-[1,2,4]triazol[4,3-b]piridazina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar cancer
|
|
EP2673277A1
(en)
|
2011-02-10 |
2013-12-18 |
Novartis AG |
[1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
|
|
US20140088114A1
(en)
|
2011-05-16 |
2014-03-27 |
OSI Pharmaceuticals ,LLC |
Fused bicyclic kinase inhibitors
|
|
EP2755976B1
(en)
|
2011-09-15 |
2018-07-18 |
Novartis AG |
6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyridines as c-met tyrosine kinase inhibitors
|
|
MX356683B
(es)
|
2011-09-27 |
2018-06-08 |
Genfit |
Derivados de triazolpiridazinas 6-sustituidas como agonistas rev-erb.
|
|
KR101869534B1
(ko)
*
|
2012-03-05 |
2018-06-20 |
한국화학연구원 |
신규한 트리아졸로 피리다진 유도체 및 그의 용도
|
|
KR20140144726A
(ko)
|
2012-03-30 |
2014-12-19 |
리젠 파마슈티컬스 소시에떼 아노님 |
C-met 단백질 키나제의 조절제로서의 신규한 3,5-디치환-3h-이미다조[4,5-b]피리딘 및 3,5- 디치환 -3h-[1,2,3]트리아졸로[4,5-b] 피리딘 화합물
|
|
AU2013290444B2
(en)
|
2012-07-16 |
2018-04-26 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions of (R)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof
|
|
CN103122000B
(zh)
*
|
2012-09-03 |
2013-12-25 |
中美冠科生物技术(太仓)有限公司 |
用作抗肿瘤药物的高选择性的c-Met激酶抑制剂
|
|
ME02794B
(me)
|
2012-10-16 |
2018-01-20 |
Janssen Pharmaceutica Nv |
Metilen vezani hinolinil modulatori ror-gama-t
|
|
JP6250686B2
(ja)
|
2012-10-16 |
2017-12-20 |
ヤンセン ファーマシューティカ エヌ.ベー. |
Rorγtのヘテロアリール結合させたキノリニルモジュレータ
|
|
US9309222B2
(en)
|
2012-10-16 |
2016-04-12 |
Janssen Pharmaceutica Nv |
Phenyl linked quinolinyl modulators of RORγt
|
|
WO2014133526A1
(en)
|
2013-02-28 |
2014-09-04 |
Empire Technology Development Llc |
Colored pigment particles for electrophoretic displays
|
|
EP3404032B1
(en)
|
2013-03-13 |
2025-07-02 |
F. Hoffmann-La Roche AG |
Process for making benzoxazepin compounds
|
|
US20140303121A1
(en)
|
2013-03-15 |
2014-10-09 |
Plexxikon Inc. |
Heterocyclic compounds and uses thereof
|
|
DK2970265T3
(en)
*
|
2013-03-15 |
2018-10-01 |
Plexxikon Inc |
HETEROCYCLIC COMPOUNDS AND APPLICATIONS THEREOF
|
|
ES2770727T3
(es)
|
2013-10-15 |
2020-07-02 |
Janssen Pharmaceutica Nv |
Moduladores de quinilonila enlazados a alquilo de ROR(gamma)t
|
|
US10555941B2
(en)
|
2013-10-15 |
2020-02-11 |
Janssen Pharmaceutica Nv |
Alkyl linked quinolinyl modulators of RORγt
|
|
US9328095B2
(en)
|
2013-10-15 |
2016-05-03 |
Janssen Pharmaceutica Nv |
Heteroaryl linked quinolinyl modulators of RORgammat
|
|
ES2742843T3
(es)
|
2013-10-15 |
2020-02-17 |
Janssen Pharmaceutica Nv |
Moduladores de quinolinilo de ROR(gamma)t
|
|
US9403816B2
(en)
|
2013-10-15 |
2016-08-02 |
Janssen Pharmaceutica Nv |
Phenyl linked quinolinyl modulators of RORγt
|
|
US9221804B2
(en)
|
2013-10-15 |
2015-12-29 |
Janssen Pharmaceutica Nv |
Secondary alcohol quinolinyl modulators of RORγt
|
|
US9284308B2
(en)
|
2013-10-15 |
2016-03-15 |
Janssen Pharmaceutica Nv |
Methylene linked quinolinyl modulators of RORγt
|
|
GB201321745D0
(en)
*
|
2013-12-09 |
2014-01-22 |
Ucb Pharma Sa |
Therapeutic agents
|
|
WO2015134854A2
(en)
*
|
2014-03-06 |
2015-09-11 |
Oyagen, Inc. |
Small molecule vif dimerization antagonists as anti-hiv agents and for use as hiv/aids therapeutics
|
|
CA2944140C
(en)
|
2014-04-15 |
2022-10-04 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
|
|
CA2957785C
(en)
|
2014-08-11 |
2023-01-03 |
Angion Biomedica Corporation |
Cytochrome p450 inhibitors and uses thereof
|
|
WO2016109492A1
(en)
|
2014-12-31 |
2016-07-07 |
Angion Biomedica Corp |
Methods and agents for treating disease
|
|
CA2980460A1
(en)
|
2015-04-13 |
2016-10-20 |
Five Prime Therapeutics, Inc. |
Combination therapy for cancer
|
|
RU2748884C2
(ru)
|
2015-07-20 |
2021-06-01 |
Джензим Корпорейшн |
Ингибиторы рецептора колониестимулирующего фактора-1 (csf-1r)
|
|
EP3694855A1
(en)
|
2017-10-13 |
2020-08-19 |
Plexxikon Inc. |
Solid forms of a compound for modulating kinases
|
|
GB201905721D0
(en)
|
2019-04-24 |
2019-06-05 |
Univ Dundee |
Compounds
|
|
CN113861198B
(zh)
*
|
2020-06-30 |
2024-08-02 |
上海医药集团股份有限公司 |
咪唑并[4,5-b]吡嗪类化合物、其制备方法及应用
|
|
JP2024500919A
(ja)
|
2020-12-23 |
2024-01-10 |
ジェンザイム・コーポレーション |
重水素化コロニー刺激因子-1受容体(csf-1r)阻害剤
|